PEGGIE PERKINS: Open Payments
NPI 1598369720 · FLEMINGTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$521 in 40 payments from 13 companies in 2025. Trend: 2023 $1,039 · 2024 $999 · 2025 $521
Food & beverage: $521
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $160 |
| Novo Nordisk Inc | 13 | $150 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Lundbeck LLC | 1 | $19 |
| Soleno Therapeutics, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Hologic Sales and Service, LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
Products named: Wegovy, QULIPTA, UBRELVY, VRAYLAR, Ozempic, XIFAXAN, Rybelsus, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
